×

Merck stops trials of blood cancer drug after risk assessment

By Thomson Reuters Nov 17, 2026 | 3:48 PM

Nov 17 (Reuters) – Merck said on Tuesday it would stop development of ​its experimental blood ‌cancer drug, nemtabrutinib, after a review found the treatment’s benefits may not outweigh its ‌risks.

An ​independent monitoring committee ⁠reached that conclusion ⁠after reviewing results from a late-stage study of the drug. Merck said ​its review of the full data confirmed ⁠the finding.

The drugmaker ⁠did not disclose ​what risks were found. It ​did not immediately respond to ‌a Reuters request for comment.

The company will also discontinue two other ⁠late-stage trials of the drug. The oral drug was being evaluated ⁠for ‌chronic lymphocytic leukemia ⁠and other blood ​cancers.

The ‌analyses are ongoing and ​the results ⁠will be shared with the scientific community, it said.

(Reporting by Kunal Das in Bengaluru; Editing by ​Sahal Muhammed)